2,3-Dinor-6-keto-prostaglandin F1α
2,3-Dinor-6-keto-prostaglandin F1α (2,3-Dinor-6-keto-PGF1α) is the major urinary metabolite of Prostaglandin I2 (HY-A0126A). 2,3-Dinor-6-keto-prostaglandin F1α is applicable to the research of coronary heart disease.
For research use only. We do not sell to patients.
- CAS No.: 64700-71-6
- Formula: C18H30O6
- Molecular Weight:342.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
2,3-Dinor-6-keto-prostaglandin F1α exhibits acceptable stability under various storage conditions[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 64700-71-6
-
Molecular Weight 342.43
-
Formula C18H30O6
-
SMILES
C(C(CCC(O)=O)=O)[C@@H]1[C@@H](/C=C/[C@H](CCCCC)O)[C@H](O)C[C@@H]1O
-
Synonyms
2,3-Dinor-6-keto-PGF1α
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
[1]. Hamazaki T, et al. Urinary excretion of PGI2/3-M and recent N-6/3 fatty acid intake. Prostaglandins. 1989;37(4):417-424. [Content Brief]
[2]. Enzler M, et al. Determination of 6-keto prostaglandin F1α and its metabolites in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jul 15;901:67-71. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
2,3-Dinor-6-keto-prostaglandin F1α Related Classifications
HY-133941 Related Classifications
Powered by Bioz